Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Dec 9;27(12):e977-e978.
doi: 10.1093/oncolo/oyac215.

In Reply: Neoadjuvant TKI Study in Early- and Intermediate Stage Hepatocellular Carcinoma

Susanne Osanto  1   2 , F J Sherida H Woei-A-Jin  1   2 , Minneke J Coenraad  3 , Nir I Weijl  1 , Mark C Burgmans  4 , Jacobus Burggraaf  5
Affiliations
Editorial

In Reply: Neoadjuvant TKI Study in Early- and Intermediate Stage Hepatocellular Carcinoma

Susanne Osanto et al. Oncologist. .

Abstract

This letter to the editor responds to comments from Rizzo et al on recently reported results of a phase II study of dovitinib therapy for hepatocellular carcinoma.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Median mRECIST response in 12 (very) early-stage HCC was higher than in 11 intermediate-stage HCC (−45% vs. −8%; P = .0028). The 2 very early (BCLC stage 0) patients are depicted in dark grey.
See this image and copyright information in PMC

Comment on

References

    1. Rizzo A, Ricci AD, Brandi G.. Neoadjuvant dovitinib in early- and intermediate-stage hepatocellular carcinoma. Oncologist. 2022;27:e976. 10.1093/oncolo/oyac168. - DOI - PMC - PubMed
    1. Woei-A-Jin FJSH, Weijl NI, Burgmans MC, et al. . Neoadjuvant treatment with angiogenesis-inhibitor dovitinib prior to local therapy in hepatocellular carcinoma: A phase II study. Oncologist. 2021;26(10):854-864. 10.1002/onco.13901 - DOI - PMC - PubMed
    1. Cheng AL, Thongprasert S, Lim HY, et al. . Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma. Hepatology. 2016;64:774-784. 10.1002/hep.28600 - DOI - PubMed
    1. Papatheodoridi M, Tampaki M, Lok AS, Papatheodoridis GV.. Risk of hbv reactivation during therapies for hcc: a systematic review. Hepatology. 2021;75:1257-1274. 10.1002/hep.32241 - DOI - PubMed
    1. Ott PA, Adams S.. Small-molecule protein kinase inhibitors and their effects on the immune system: implications for cancer treatment. Immunotherapy. 2011;3:213-227. 10.2217/imt.10.99 - DOI - PMC - PubMed

MeSH terms